Halozyme and Skye Bioscience Enter Global Collaboration Agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2026
0mins
Should l Buy HALO?
Halozyme Therapeutics (HALO) and Skye Bioscience (SKYE) announced the companies entered into a non-exclusive global collaboration and license agreement in December 2025. Under the collaboration, Skye has licensed Halozyme's ENHANZE drug delivery technology for the development and potential commercialization of a subcutaneous formulation of nimacimab for the treatment of obesity. The collaboration is intended to support Skye's evaluation of higher nimacimab subcutaneous doses through delivery of larger injection volumes. Skye will make milestone payments tied to the achievement of certain development and commercialization events. Halozyme will also be entitled to mid-single digit royalties on net sales of nimacimab developed with ENHANZE for at least 10 years. Skye is planning to initiate a Phase 2b clinical trial in obesity for nimacimab with ENHANZE in the middle of 2026. This study will also assess the combination of nimacimab and a GLP-1R agonist.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HALO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HALO
Wall Street analysts forecast HALO stock price to rise
5 Analyst Rating
3 Buy
1 Hold
1 Sell
Moderate Buy
Current: 69.530
Low
56.00
Averages
78.50
High
90.00
Current: 69.530
Low
56.00
Averages
78.50
High
90.00
About HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Halozyme Announces Upcoming Investor Conference Presentations
- Investor Conference Schedule: Halozyme Therapeutics is set to participate in the TD Cowen 46th Annual Healthcare Conference on March 3, 2026, in Boston, where CEO Dr. Helen Torley will engage in a fireside chat and one-on-one meetings, enhancing the company's interaction with investors.
- Multiple Conference Appearances: Following this, Halozyme will also attend the Leerink Partners Global Healthcare Conference on March 10 and the Citizens Life Sciences Conference on March 11, showcasing its innovations in the biopharmaceutical sector and further elevating its visibility among investors.
- Showcasing Technological Innovations: With its ENHANZE® drug delivery technology at the forefront, Halozyme has launched ten commercial products globally, impacting over one million patients, which highlights its potential in improving patient experiences and outcomes, likely attracting more investor interest.
- Future Growth Potential: The company is also developing Hypercon™ and Surf Bio hyperconcentration technologies, aimed at expanding the applications of drug delivery technologies, enhancing patient convenience and adherence, which could provide new momentum for future market growth.
See More
Halozyme Reports Q4 2026 Earnings Miss, Stock Drops
- Disappointing Earnings: Halozyme reported a non-GAAP EPS of -$0.24 for Q4 2026, a significant drop from $1.26 in the same period last year, indicating a notable decline in profitability that could undermine investor confidence.
- 2026 EPS Guidance: The company reiterated its 2026 non-GAAP EPS guidance range of $7.75-$8.25, with a midpoint of $8.00, which is below the consensus estimate of $8.15, suggesting potential pressure on future earnings expectations.
- Revenue Outlook: Halozyme anticipates 2026 revenue between $1.71B and $1.81B, with a midpoint of $1.76B, slightly below the consensus of $1.77B, reflecting a cautious market sentiment regarding its growth potential.
- Deteriorating Cash Position: As of the end of 2025, Halozyme's cash, cash equivalents, and marketable securities totaled $145.4M, a sharp decline from $596.1M at the end of 2024, indicating challenges in cash management that may impact future investment capabilities.
See More
Halozyme Therapeutics Q4 2025 Earnings Call Highlights
- Significant Revenue Growth: Halozyme reported total revenue of $1.4 billion for 2025, reflecting a 38% year-over-year increase, with Q4 revenue at $451.8 million, showcasing sustained momentum from ENHANZE technology that is expected to drive future revenue growth.
- Patent Technology Expansion: The acquisition of Elektrofi and Surf Bio has expanded Halozyme's subcutaneous drug delivery technologies from two to four, solidifying its market position in the biopharma industry as a 'one-stop shop' for drug delivery solutions.
- Strong Royalty Revenue: The company generated $867.8 million in royalty revenue for 2025, primarily driven by successful products like Johnson & Johnson's DARZALEX and Roche's PHESGO, which are expected to continue providing stable cash flow for the company.
- Optimistic Future Outlook: Management projects total revenue for 2026 to be between $1.71 billion and $1.81 billion, with royalty revenues expected to range from $1.13 billion to $1.17 billion, reflecting confidence in future growth driven by new technologies and partnerships.
See More
Halozyme Reports Strong Q4 and 2025 Revenue Growth
- Earnings Performance: Halozyme reported a Q4 non-GAAP EPS of -$0.24, missing estimates by $2.44, yet achieved revenue of $451 million, a 51.3% year-over-year increase, exceeding expectations by $4.86 million, indicating strong revenue growth.
- Annual Results: For the full year 2025, total revenue reached a record $1.397 billion, up 38% year-over-year, while royalty revenue increased by 52% to $868 million, reflecting the company's competitive strength and sustained product demand in the market.
- Acquisition Strategy: The completion of acquisitions of Elektrofi's Hypercon™ technology and Surf Bio's hyperconcentration technology will provide significant support for future growth, enhancing the company's product portfolio and market position.
- Financial Guidance: The company reiterated its 2026 financial guidance, projecting total revenue between $1.710 billion and $1.810 billion, with year-over-year growth of 22% to 30%, and adjusted EBITDA expected between $1.125 billion and $1.205 billion, demonstrating confidence in future growth prospects.
See More
Halozyme Therapeutics Q4 Earnings Preview
- Earnings Announcement Date: Halozyme Therapeutics (HALO) is set to release its Q4 earnings on February 17th after market close, with a consensus EPS estimate of $2.20, reflecting a robust 74.6% year-over-year growth, indicating strong profitability and market confidence.
- Revenue Growth Expectations: The anticipated revenue for Q4 is $446.13 million, representing a 49.7% year-over-year increase, which underscores Halozyme's sustained growth in the biopharmaceutical sector and strong market demand.
- Performance Beat Record: Over the past two years, HALO has beaten EPS estimates 88% of the time and revenue estimates 75% of the time, demonstrating the company's financial stability and effective management execution.
- Upward Revision Trend: In the last three months, EPS estimates have seen five upward revisions and revenue estimates six, reflecting analysts' optimistic outlook on Halozyme's future performance, which further boosts investor confidence.
See More
Halozyme Acquires Three Biotech Startups for $1.3 Billion
- Accelerated Acquisition Activity: Halozyme has recently spent up to $1.3 billion acquiring three biotech startups, indicating its intent to expand in the biopharma sector, which is expected to enhance its market competitiveness.
- Drug Delivery Innovation: The acquisition of hyper-concentration technology allows Halozyme to deliver drugs in smaller volumes, significantly improving patient experience and reducing stress on the healthcare system by enabling quicker administration.
- Optimistic Market Outlook: The CEO of Halozyme noted that M&A activity in the biotech sector is forecasted to accelerate in 2026, reflecting increased confidence in innovative drugs and driving the company's proactive strategies in drug development and marketing.
- Revenue Growth Potential: Halozyme's current technologies have received 10 approvals and are projected to generate $1 billion in royalty revenues by 2026, showcasing its strong profitability and market demand in the drug delivery space.
See More
Halozyme Announces Upcoming Investor Conference Presentations
- Investor Conference Schedule: Halozyme Therapeutics is set to participate in the TD Cowen 46th Annual Healthcare Conference on March 3, 2026, in Boston, where CEO Dr. Helen Torley will engage in a fireside chat and one-on-one meetings, enhancing the company's interaction with investors.
- Multiple Conference Appearances: Following this, Halozyme will also attend the Leerink Partners Global Healthcare Conference on March 10 and the Citizens Life Sciences Conference on March 11, showcasing its innovations in the biopharmaceutical sector and further elevating its visibility among investors.
- Showcasing Technological Innovations: With its ENHANZE® drug delivery technology at the forefront, Halozyme has launched ten commercial products globally, impacting over one million patients, which highlights its potential in improving patient experiences and outcomes, likely attracting more investor interest.
- Future Growth Potential: The company is also developing Hypercon™ and Surf Bio hyperconcentration technologies, aimed at expanding the applications of drug delivery technologies, enhancing patient convenience and adherence, which could provide new momentum for future market growth.
See More
Halozyme Reports Q4 2026 Earnings Miss, Stock Drops
- Disappointing Earnings: Halozyme reported a non-GAAP EPS of -$0.24 for Q4 2026, a significant drop from $1.26 in the same period last year, indicating a notable decline in profitability that could undermine investor confidence.
- 2026 EPS Guidance: The company reiterated its 2026 non-GAAP EPS guidance range of $7.75-$8.25, with a midpoint of $8.00, which is below the consensus estimate of $8.15, suggesting potential pressure on future earnings expectations.
- Revenue Outlook: Halozyme anticipates 2026 revenue between $1.71B and $1.81B, with a midpoint of $1.76B, slightly below the consensus of $1.77B, reflecting a cautious market sentiment regarding its growth potential.
- Deteriorating Cash Position: As of the end of 2025, Halozyme's cash, cash equivalents, and marketable securities totaled $145.4M, a sharp decline from $596.1M at the end of 2024, indicating challenges in cash management that may impact future investment capabilities.
See More
Halozyme Therapeutics Q4 2025 Earnings Call Highlights
- Significant Revenue Growth: Halozyme reported total revenue of $1.4 billion for 2025, reflecting a 38% year-over-year increase, with Q4 revenue at $451.8 million, showcasing sustained momentum from ENHANZE technology that is expected to drive future revenue growth.
- Patent Technology Expansion: The acquisition of Elektrofi and Surf Bio has expanded Halozyme's subcutaneous drug delivery technologies from two to four, solidifying its market position in the biopharma industry as a 'one-stop shop' for drug delivery solutions.
- Strong Royalty Revenue: The company generated $867.8 million in royalty revenue for 2025, primarily driven by successful products like Johnson & Johnson's DARZALEX and Roche's PHESGO, which are expected to continue providing stable cash flow for the company.
- Optimistic Future Outlook: Management projects total revenue for 2026 to be between $1.71 billion and $1.81 billion, with royalty revenues expected to range from $1.13 billion to $1.17 billion, reflecting confidence in future growth driven by new technologies and partnerships.
See More
Halozyme Reports Strong Q4 and 2025 Revenue Growth
- Earnings Performance: Halozyme reported a Q4 non-GAAP EPS of -$0.24, missing estimates by $2.44, yet achieved revenue of $451 million, a 51.3% year-over-year increase, exceeding expectations by $4.86 million, indicating strong revenue growth.
- Annual Results: For the full year 2025, total revenue reached a record $1.397 billion, up 38% year-over-year, while royalty revenue increased by 52% to $868 million, reflecting the company's competitive strength and sustained product demand in the market.
- Acquisition Strategy: The completion of acquisitions of Elektrofi's Hypercon™ technology and Surf Bio's hyperconcentration technology will provide significant support for future growth, enhancing the company's product portfolio and market position.
- Financial Guidance: The company reiterated its 2026 financial guidance, projecting total revenue between $1.710 billion and $1.810 billion, with year-over-year growth of 22% to 30%, and adjusted EBITDA expected between $1.125 billion and $1.205 billion, demonstrating confidence in future growth prospects.
See More
Halozyme Therapeutics Q4 Earnings Preview
- Earnings Announcement Date: Halozyme Therapeutics (HALO) is set to release its Q4 earnings on February 17th after market close, with a consensus EPS estimate of $2.20, reflecting a robust 74.6% year-over-year growth, indicating strong profitability and market confidence.
- Revenue Growth Expectations: The anticipated revenue for Q4 is $446.13 million, representing a 49.7% year-over-year increase, which underscores Halozyme's sustained growth in the biopharmaceutical sector and strong market demand.
- Performance Beat Record: Over the past two years, HALO has beaten EPS estimates 88% of the time and revenue estimates 75% of the time, demonstrating the company's financial stability and effective management execution.
- Upward Revision Trend: In the last three months, EPS estimates have seen five upward revisions and revenue estimates six, reflecting analysts' optimistic outlook on Halozyme's future performance, which further boosts investor confidence.
See More
Halozyme Acquires Three Biotech Startups for $1.3 Billion
- Accelerated Acquisition Activity: Halozyme has recently spent up to $1.3 billion acquiring three biotech startups, indicating its intent to expand in the biopharma sector, which is expected to enhance its market competitiveness.
- Drug Delivery Innovation: The acquisition of hyper-concentration technology allows Halozyme to deliver drugs in smaller volumes, significantly improving patient experience and reducing stress on the healthcare system by enabling quicker administration.
- Optimistic Market Outlook: The CEO of Halozyme noted that M&A activity in the biotech sector is forecasted to accelerate in 2026, reflecting increased confidence in innovative drugs and driving the company's proactive strategies in drug development and marketing.
- Revenue Growth Potential: Halozyme's current technologies have received 10 approvals and are projected to generate $1 billion in royalty revenues by 2026, showcasing its strong profitability and market demand in the drug delivery space.
See More
